Every 10-Q that VSEE HEALTH INC (VSEE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VSEE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSEE filings page.
VSee Health, Inc. operates a telehealth services business centered on iDoc and reports continued losses and liquidity pressure for the quarter ended June 30, 2026. From continuing operations, revenue rose to $1.56 million for the quarter and $3.44 million for the first six months of 2026, up from $1.06 million and $2.25 million in the prior-year periods, but gross margin compressed and operating expenses increased, leading to a six‑month loss from continuing operations of $4.34 million.
Including discontinued operations, the company recorded net income driven by the May 31, 2026 divestiture of VSee Lab to former co‑CEO Milton Chen, recognizing a $4.17 million gain and cancelling 2,870,069 common shares. Cash fell sharply to $454,151 from $5.05 million at year‑end, with $2.50 million of operating cash outflows from continuing operations in the first half. Total assets were $16.73 million and total liabilities $9.14 million, leaving equity of $7.59 million. Management states that recurring losses, an accumulated deficit of $84.17 million, and limited liquidity raise substantial doubt about the company’s ability to continue as a going concern, despite past funding through debt and equity and ongoing efforts to improve its position.
VSee Health, Inc. reported first‑quarter 2026 revenue of $3.16 million, compared with $3.32 million in the prior‑year quarter. Gross margin was $1.20 million while operating expenses rose to $4.17 million, leading to a net operating loss of $2.97 million.
Net loss narrowed to $2.60 million versus $3.96 million a year earlier, helped by a $367,809 gain on extinguishment of financial liabilities and a $143,040 gain from changes in fair value of financial instruments. Basic and diluted loss per share was $0.05 on a weighted average of 47.9 million shares.
Cash declined to $1.35 million from $5.27 million at December 31, 2025, with operating activities using $2.45 million of cash in the quarter. The company ended the period with total assets of $19.0 million, liabilities of $12.7 million, and stockholders’ equity of $6.32 million, alongside an accumulated deficit of $85.0 million. Management states that recurring losses and liquidity conditions raise substantial doubt about VSee Health’s ability to continue as a going concern.
VSee Health, Inc. filed an amended Form 10-Q/A reporting much higher Q2 2025 revenue but deeper losses and a weak balance sheet. For the three months ended June 30, 2025, revenue rose to $3.39 million from $1.71 million a year earlier, while the net loss widened to $2.61 million from $0.67 million. For the six months, revenue was $6.71 million with a net loss of $6.57 million and a basic loss per share of $0.40.
At June 30, 2025, the company had cash of $291,595, total assets of $18.2 million, liabilities of $23.95 million, and a stockholders’ deficit of $5.74 million, and management states that recurring losses and liquidity issues raise substantial doubt about continuing as a going concern. The amendment also restates VSee Lab’s Q2 2024 standalone financials after identifying material errors, reducing previously reported stockholders’ equity by about $1.71 million.
VSee Health (VSEE) filed its quarterly report detailing higher revenue and ongoing losses with a going concern warning. For the three months ended June 30, 2025, revenue was $3,390,119, up from $1,711,566 a year ago, driven by professional services, technical engineering, patient fees, and telehealth fees. Gross margin was $1,588,492.
The company reported a net loss of $2,613,283 for the quarter versus $666,102 in the prior year period, and a six‑month net loss of $6,572,723 versus $571,352. Operating expenses rose to $3,843,232 in the quarter. Cash was $291,595 at June 30, 2025. Current liabilities were $23,058,308, and total liabilities exceeded assets, resulting in a stockholders’ deficit of $5,736,304.
Management states that liquidity conditions and historical operating losses raise substantial doubt about the company’s ability to continue as a going concern. The company recorded deferred revenue of $1,170,101 and an allowance for credit losses of $2,639,917. VSee maintains two segments (Healthcare Technology and Telehealth Services) and disclosed March and May 2025 convertible and promissory notes. Previous 2024 quarterly results were restated.
VSee Health (VSEE) filed its Q1 2025 10‑Q, reporting total revenues of $3,321,485, up from $1,620,995 a year ago as telehealth services, patient fees, and technical engineering expanded. Despite higher sales, the company posted a net loss of $3,959,440 versus net income of $62,770 in the prior-year period.
Gross margin was $1,859,971, but higher operating expenses of $3,691,289 and other expenses weighed on results, including interest expense of $730,665 and a $1,261,471 loss from changes in fair value of financial instruments. Cash used in operations was $440,493; cash ended at $410,122. The balance sheet shows assets of $19,395,686 against total liabilities of $22,892,683, resulting in a stockholders’ deficit of $3,496,997.
The company disclosed a going concern uncertainty due to historical losses and liquidity pressures. It also restated VSee Lab’s Q1 2024 standalone results, adjusting revenue and expenses. Management continues to pursue financing arrangements, including convertible and secured notes, to support operations.